NCT07131722 2026-01-23Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type IIPRG Science & Technology Co., Ltd.Phase 1/2 Not yet recruiting25 enrolled